Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Two-Part Open Label Phase 1 Multicentre Study Evaluating the Safety of INT2104 Infusions in Female and Male Participants Aged 18 Years of Age and Older With Refractory/Relapsing B-cell Malignancies

Next Previous
Trial Profile

A Two-Part Open Label Phase 1 Multicentre Study Evaluating the Safety of INT2104 Infusions in Female and Male Participants Aged 18 Years of Age and Older With Refractory/Relapsing B-cell Malignancies

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 19 Aug 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs INT 2104 (Primary)
  • Indications B-cell lymphoma; Burkitt's lymphoma; Non-Hodgkin's lymphoma; Precursor cell lymphoblastic leukaemia-lymphoma
  • Focus Adverse reactions; First in man; Proof of concept
  • Acronyms INVISE
  • Sponsors Interius BioTherapeutics

Most Recent Events

  • 29 Jul 2025 Planned number of patients changed from 30 to 34.
  • 17 Apr 2025 According to an Interius BioTherapeutics media release, data from this trial will be presented at the International Society for Cell and Gene Therapy (ISCT) 2025 Annual Meeting.
  • 07 Jan 2025 According to an Interius BioTherapeutics media release, the interim safety and proof-of-concept data to be presented at a scientific meeting in 2H 2025

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top